Joseph P Dougherty

US Patent:

7198909, Apr 3, 2007

Filed:

Oct 29, 1999

Appl. No.:

09/830176

Inventors:

Yacov Ron - East Brunswick NJ, US
Joseph P. Dougherty - Hampton NJ, US

Assignee:

University of Medicine & Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12P 21/06
C12P 21/00

US Classification:

435 691, 435 701

Abstract:

A long-lived, myeloid-committed stem cell population is disclosed. Also disclosed are methods and compositions for targeting this population with retrovirus vectors in gene therapy protocols for correcting congenital disorders of myeloid system and for potentiating immune responses to defined tumor and viral antigens.

US Patent:

56889151, Nov 18, 1997

Filed:

Jun 1, 1995

Appl. No.:

8/457482

Inventors:

Yakov Ron - East Brunswick NJ
Joseph Dougherty - Hampton NJ

Assignee:

The University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 500
C12N 508
C12Q 104

US Classification:

530380

Abstract:

Long term culture of resting T lymphocytes. The present invention provides methods and compositions for maintaining resting, mature T lymphocytes (cells) for long term in the absence of mitogens, antigens, or stimulatory cytokines, in which the T cells maintaining their ability to respond to nitrogens and allogenic cells. T cells cultured under such conditions can be used as target cells for retroviral vector-mediated gene transfer and implemented in certain gene therapy applications. The culturing conditions described herein allow for the continuous availability of T lymphocytes for various pharmacological, diagnostic, gene therapy, and experimental purposes, and can be utilized for any application requiring non-stimulated T lymphocytes. In specific examples, umbilical cord blood and peripheral blood T lymphocytes and endothelial-like adherent monocytes are cultured in DMEM, 2% 2-mercaptoethanol containing either 20% horse serum, or RPMI 2% 2-ME containing 10% fetal calf serum supplemented with basic fibroblast growth factor for up to three months.